⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGIO News
Agios Pharmaceuticals, Inc.
Agios, Partner von Avanzanite Bioscience, gibt die Zulassung von PYRUKYND® (Mitapivat) in der Europäischen Union für Erwachsene mit Thalassämie bekannt
businesswire.com
AGIO
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
businesswire.com
AGIO
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
globenewswire.com
AGIO
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
globenewswire.com
AGIO
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
globenewswire.com
AGIO
Form 8-K
sec.gov
AGIO
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
AGIO
Santhera Appoints Orlando Oliveira as Chief Executive Officer
globenewswire.com
AMGN
AGIO
CPRX
ZENA
Alpha Thalassemia (US, EU4, UK, and Japan) Market Insights, Epidemiology, and Forecasts 2022-2025 & 2025-2036
globenewswire.com
AGIO
NVO
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
globenewswire.com
AGIO